Immunotherapy plus chemo before surgery for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether adding a new immunotherapy drug (ivonescimab or penpulimab) to standard chemotherapy before surgery helps people with early-stage lung cancer. It's for people whose cancer can be surgically removed and who haven't had treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage II or III non-small cell lung cancer that can be removed with surgery.
- You have not had any prior treatment for your lung cancer, like chemotherapy or radiation.
- Your cancer does not have an EGFR mutation or ALK gene change (if you have non-squamous type).
- You are generally healthy enough for surgery and have normal heart, lung, and blood function.
- You have not had another cancer in the last 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a new drug called Ivonescimab can improve outcomes when given before surgery for non-small cell lung cancer. It may help shrink tumors and make them easier to remove.
This trial tests adding the immunotherapy drug Adebrelimab to standard chemotherapy before surgery for people with stage II or III non-small cell lung cancer (the most common type) that can be removed. The goal is to see if this combination shrinks tumors more effectively and improves outcomes.
This trial tests whether giving chemotherapy plus immunotherapy before surgery helps people with a specific type of advanced lung cancer. It aims to see if this approach can shrink tumors and make surgery more effective.
This trial tests a new immunotherapy drug (ivonescimab, also called AK112) combined with chemotherapy before surgery for people with esophageal squamous cell cancer that can be completely removed. The goal is to see if adding immunotherapy before surgery helps shrink the tumor and improve outcomes.
This study tests a combination of the immunotherapy drug atezolizumab with standard chemotherapy given before surgery for people with stage II to IIIB non-small cell lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improve outcomes.
This Phase 2 study looks at whether adding an immunotherapy medicine (camrelizumab) to standard chemotherapy after lung surgery can help prevent lung cancer from coming back. It is for people with stage IIA–IIIA non-small cell lung cancer who cannot use targeted (mutation-based) adjuvant therapy.
Hear when a new Neoadjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.